Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:46:13 18/06/2024 pm IST			5-day change	1st Jan Change
474.8 ^USD	+0.24%		-1.46%	+16.61%

17/06	Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	MT
14/06	Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	MT

Declaration of Voting Results by Vertex Pharmaceuticals Incorporated

May 16, 2024 at 01:42 am IST

On May 15, 2024, Vertex Pharmaceuticals Incorporated announced that it held its annual general meeting of shareholders on May 15, 2024, and declared voting results. Accordingly, a shareholder proposal regarding a report on racial and gender pay gaps submitted by Arjuna Capital, representing its clients, John Silva and Shana Weiss, was not approved by the Company shareholders.

Latest news about Vertex Pharmaceuticals Incorporated

Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	17/06	MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	14/06	MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel)	14/06	CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing	14/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing	14/06	MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	11/06
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424	11/06	MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients	07/06	MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA	07/06	CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing	06/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing	06/06	MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM	05/06
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing	04/06	MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	30/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	23/05	MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment	21/05	MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders.	20/05	CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated	16/05	CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated	16/05	CI
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director	15/05	CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497	14/05	MT
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	11/05	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.7 USD

Average target price

463.4 USD

Spread / Average Target

-2.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+18.89%	113B
ARGENX SE	+2.42%	22.66B
BIONTECH SE	-16.64%	21.34B
WUXI APPTEC CO., LTD.	-39.57%	16.92B
BEIGENE, LTD.	-13.93%	16.68B
GENMAB A/S	-16.33%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+2.90%	13.62B
SAREPTA THERAPEUTICS, INC.	+21.59%	11.04B
INSMED INCORPORATED	+108.20%	10.43B

Bio Therapeutic Drugs